Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

An Eye on Staphylococcus aureus Toxins: Roles in Ocular Damage and Inflammation.

Astley R, Miller FC, Mursalin MH, Coburn PS, Callegan MC.

Toxins (Basel). 2019 Jun 19;11(6). pii: E356. doi: 10.3390/toxins11060356. Review.

2.

Ocular Glands Become Infected Secondarily to Infectious Keratitis and Play a Role in Corneal Resistance to Infection.

Montgomery ML, Callegan MC, Fuller KK, Carr DJJ.

J Virol. 2019 Jul 30;93(16). pii: e00314-19. doi: 10.1128/JVI.00314-19. Print 2019 Aug 15.

PMID:
31167909
3.

Targets of immunomodulation in bacterial endophthalmitis.

Miller FC, Coburn PS, Huzzatul MM, LaGrow AL, Livingston E, Callegan MC.

Prog Retin Eye Res. 2019 May 28. pii: S1350-9462(19)30027-8. doi: 10.1016/j.preteyeres.2019.05.004. [Epub ahead of print] Review.

PMID:
31150824
4.

Disarming Pore-Forming Toxins with Biomimetic Nanosponges in Intraocular Infections.

Coburn PS, Miller FC, LaGrow AL, Land C, Mursalin H, Livingston E, Amayem O, Chen Y, Gao W, Zhang L, Callegan MC.

mSphere. 2019 May 15;4(3). pii: e00262-19. doi: 10.1128/mSphere.00262-19.

5.

TLR4 modulates inflammatory gene targets in the retina during Bacillus cereus endophthalmitis.

Coburn PS, Miller FC, LaGrow AL, Parkunan SM, Blake Randall C, Staats RL, Callegan MC.

BMC Ophthalmol. 2018 Apr 16;18(1):96. doi: 10.1186/s12886-018-0764-8.

6.

A Novel Biomimetic Nanosponge Protects the Retina from the Enterococcus faecalis Cytolysin.

LaGrow AL, Coburn PS, Miller FC, Land C, Parkunan SM, Luk BT, Gao W, Zhang L, Callegan MC.

mSphere. 2017 Nov 22;2(6). pii: e00335-17. doi: 10.1128/mSphere.00335-17. eCollection 2017 Nov-Dec.

7.

The role of pili in Bacillus cereus intraocular infection.

Callegan MC, Parkunan SM, Randall CB, Coburn PS, Miller FC, LaGrow AL, Astley RA, Land C, Oh SY, Schneewind O.

Exp Eye Res. 2017 Jun;159:69-76. doi: 10.1016/j.exer.2017.03.007. Epub 2017 Mar 20.

8.

CXCL1, but not IL-6, significantly impacts intraocular inflammation during infection.

Parkunan SM, Randall CB, Astley RA, Furtado GC, Lira SA, Callegan MC.

J Leukoc Biol. 2016 Nov;100(5):1125-1134. Epub 2016 Jun 10.

9.

Bloodstream-To-Eye Infections Are Facilitated by Outer Blood-Retinal Barrier Dysfunction.

Coburn PS, Wiskur BJ, Miller FC, LaGrow AL, Astley RA, Elliott MH, Callegan MC.

PLoS One. 2016 May 19;11(5):e0154560. doi: 10.1371/journal.pone.0154560. eCollection 2016.

10.

Modeling intraocular bacterial infections.

Astley RA, Coburn PS, Parkunan SM, Callegan MC.

Prog Retin Eye Res. 2016 Sep;54:30-48. doi: 10.1016/j.preteyeres.2016.04.007. Epub 2016 May 3. Review.

11.

Blood-Retinal Barrier Compromise and Endogenous Staphylococcus aureus Endophthalmitis.

Coburn PS, Wiskur BJ, Astley RA, Callegan MC.

Invest Ophthalmol Vis Sci. 2015 Nov;56(12):7303-11. doi: 10.1167/iovs.15-17488.

12.

Unexpected Roles for Toll-Like Receptor 4 and TRIF in Intraocular Infection with Gram-Positive Bacteria.

Parkunan SM, Randall CB, Coburn PS, Astley RA, Staats RL, Callegan MC.

Infect Immun. 2015 Oct;83(10):3926-36. doi: 10.1128/IAI.00502-15. Epub 2015 Jul 20.

13.

Caveolin-1 increases proinflammatory chemoattractants and blood-retinal barrier breakdown but decreases leukocyte recruitment in inflammation.

Li X, Gu X, Boyce TM, Zheng M, Reagan AM, Qi H, Mandal N, Cohen AW, Callegan MC, Carr DJ, Elliott MH.

Invest Ophthalmol Vis Sci. 2014 Aug 26;55(10):6224-34. doi: 10.1167/iovs.14-14613.

14.

Role of TLR5 and flagella in bacillus intraocular infection.

Parkunan SM, Astley R, Callegan MC.

PLoS One. 2014 Jun 24;9(6):e100543. doi: 10.1371/journal.pone.0100543. eCollection 2014.

15.

TLR4 contributes to the host response to Klebsiella intraocular infection.

Hunt JJ, Astley R, Wheatley N, Wang JT, Callegan MC.

Curr Eye Res. 2014 Aug;39(8):790-802. doi: 10.3109/02713683.2014.883412. Epub 2014 Mar 3.

16.

The impact of short-term topical gatifloxacin and moxifloxacin on bacterial injection after hypodermic needle passage through human conjunctiva.

Pettey JH, Mifflin MD, Kamae K, McEntire MW, Pettey DH, Callegan MC, Brown H, Olson RJ.

J Ocul Pharmacol Ther. 2013 Jun;29(5):450-5. doi: 10.1089/jop.2012.0124. Epub 2013 Feb 20.

PMID:
23425429
17.

The diabetic ocular environment facilitates the development of endogenous bacterial endophthalmitis.

Coburn PS, Wiskur BJ, Christy E, Callegan MC.

Invest Ophthalmol Vis Sci. 2012 Nov 1;53(12):7426-31. doi: 10.1167/iovs.12-10661.

18.

Role of Toll-like receptor (TLR) 2 in experimental Bacillus cereus endophthalmitis.

Novosad BD, Astley RA, Callegan MC.

PLoS One. 2011;6(12):e28619. doi: 10.1371/journal.pone.0028619. Epub 2011 Dec 6.

19.

Contribution of mucoviscosity-associated gene A (magA) to virulence in experimental Klebsiella pneumoniae endophthalmitis.

Hunt JJ, Wang JT, Callegan MC.

Invest Ophthalmol Vis Sci. 2011 Aug 29;52(9):6860-6. doi: 10.1167/iovs.11-7798.

20.

Efficacy of vitrectomy in improving the outcome of Bacillus cereus endophthalmitis.

Callegan MC, Guess S, Wheatley NR, Woods DC, Griffin G, Wiskur BJ, Leonard R.

Retina. 2011 Sep;31(8):1518-24. doi: 10.1097/IAE.0b013e318206d176.

21.

Severe bacterial endophthalmitis: towards improving clinical outcomes.

Novosad BD, Callegan MC.

Expert Rev Ophthalmol. 2010 Oct;5(5):689-698.

22.

Checks and balances: the ocular response to infection.

Callegan MC.

Virulence. 2010 Jul-Aug;1(4):222. doi: 10.4161/viru.1.4.12317.

23.

Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones.

Callegan MC, Novosad BD, Ramadan RT, Wiskur B, Moyer AL.

Adv Ther. 2009 Apr;26(4):447-54. doi: 10.1007/s12325-009-0018-5. Epub 2009 Apr 16.

PMID:
19381523
24.

Bacillus cereus-induced permeability of the blood-ocular barrier during experimental endophthalmitis.

Moyer AL, Ramadan RT, Novosad BD, Astley R, Callegan MC.

Invest Ophthalmol Vis Sci. 2009 Aug;50(8):3783-93. doi: 10.1167/iovs.08-3051. Epub 2009 Mar 5.

25.

A role for tumor necrosis factor-alpha in experimental Bacillus cereus endophthalmitis pathogenesis.

Ramadan RT, Moyer AL, Callegan MC.

Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4482-9. doi: 10.1167/iovs.08-2085. Epub 2008 Jun 27.

26.

Hypermucoviscosity as a virulence factor in experimental Klebsiella pneumoniae endophthalmitis.

Wiskur BJ, Hunt JJ, Callegan MC.

Invest Ophthalmol Vis Sci. 2008 Nov;49(11):4931-8. doi: 10.1167/iovs.08-2276. Epub 2008 Jun 27.

27.

Toward improving therapeutic regimens for Bacillus endophthalmitis.

Wiskur BJ, Robinson ML, Farrand AJ, Novosad BD, Callegan MC.

Invest Ophthalmol Vis Sci. 2008 Apr;49(4):1480-7. doi: 10.1167/iovs.07-1303.

28.

Bacillus cereus induces permeability of an in vitro blood-retina barrier.

Moyer AL, Ramadan RT, Thurman J, Burroughs A, Callegan MC.

Infect Immun. 2008 Apr;76(4):1358-67. doi: 10.1128/IAI.01330-07. Epub 2008 Feb 11.

29.

The SAG1 Toxoplasma gondii surface protein is not required for acute ocular toxoplasmosis in mice.

Charles E, Callegan MC, Blader IJ.

Infect Immun. 2007 Apr;75(4):2079-83. Epub 2007 Feb 5.

30.

Role of bacterial and host factors in infectious endophthalmitis.

Gregory M, Callegan MC, Gilmore MS.

Chem Immunol Allergy. 2007;92:266-275. doi: 10.1159/000099277. Review.

PMID:
17264502
31.

Bacterial endophthalmitis: therapeutic challenges and host-pathogen interactions.

Callegan MC, Gilmore MS, Gregory M, Ramadan RT, Wiskur BJ, Moyer AL, Hunt JJ, Novosad BD.

Prog Retin Eye Res. 2007 Mar;26(2):189-203. Epub 2007 Jan 22. Review.

32.

Acute inflammation and loss of retinal architecture and function during experimental Bacillus endophthalmitis.

Ramadan RT, Ramirez R, Novosad BD, Callegan MC.

Curr Eye Res. 2006 Nov;31(11):955-65.

PMID:
17114121
33.

Role of swarming migration in the pathogenesis of bacillus endophthalmitis.

Callegan MC, Novosad BD, Ramirez R, Ghelardi E, Senesi S.

Invest Ophthalmol Vis Sci. 2006 Oct;47(10):4461-7.

PMID:
17003440
34.

Virulence factor profiles and antimicrobial susceptibilities of ocular bacillus isolates.

Callegan MC, Cochran DC, Kane ST, Ramadan RT, Chodosh J, McLean C, Stroman DW.

Curr Eye Res. 2006 Sep;31(9):693-702.

PMID:
16966141
35.

Bacillus endophthalmitis: roles of bacterial toxins and motility during infection.

Callegan MC, Kane ST, Cochran DC, Novosad B, Gilmore MS, Gominet M, Lereclus D.

Invest Ophthalmol Vis Sci. 2005 Sep;46(9):3233-8.

PMID:
16123424
36.

Antibacterial activity of the fourth-generation fluoroquinolones gatifloxacin and moxifloxacin against ocular pathogens.

Callegan MC, Ramirez R, Kane ST, Cochran DC, Jensen H.

Adv Ther. 2003 Sep-Oct;20(5):246-52.

PMID:
14964344
37.

Relationship of plcR-regulated factors to Bacillus endophthalmitis virulence.

Callegan MC, Kane ST, Cochran DC, Gilmore MS, Gominet M, Lereclus D.

Infect Immun. 2003 Jun;71(6):3116-24.

38.

Contribution of membrane-damaging toxins to Bacillus endophthalmitis pathogenesis.

Callegan MC, Cochran DC, Kane ST, Gilmore MS, Gominet M, Lereclus D.

Infect Immun. 2002 Oct;70(10):5381-9.

39.

Molecular mechanisms of Bacillus endophthalmitis pathogenesis.

Callegan MC, Kane ST, Cochran DC, Gilmore MS.

DNA Cell Biol. 2002 May-Jun;21(5-6):367-73. Review.

PMID:
12167238
40.

Corneal expression of the inflammatory mediator CAP37.

Ruan X, Chodosh J, Callegan MC, Booth MC, Lee TD, Kumar P, Gilmore MS, Pereira HA.

Invest Ophthalmol Vis Sci. 2002 May;43(5):1414-21.

PMID:
11980855
41.

Bacterial endophthalmitis: epidemiology, therapeutics, and bacterium-host interactions.

Callegan MC, Engelbert M, Parke DW 2nd, Jett BD, Gilmore MS.

Clin Microbiol Rev. 2002 Jan;15(1):111-24. Review.

42.

Corticosteroid and antibiotic therapy for bacillus endophthalmitis.

Callegan MC, Parke DW 2nd, Gilmore MS.

Arch Ophthalmol. 2001 Sep;119(9):1391-3. No abstract available.

PMID:
11545656
43.

Clonal associations among Staphylococcus aureus isolates from various sites of infection.

Booth MC, Pence LM, Mahasreshti P, Callegan MC, Gilmore MS.

Infect Immun. 2001 Jan;69(1):345-52. Erratum in: Infect Immun 2001 Mar;69(3):1976.

44.

In vitro pharmacodynamics of ofloxacin and ciprofloxacin against common ocular pathogens.

Callegan MC, Booth MC, Gilmore MS.

Cornea. 2000 Jul;19(4):539-45.

PMID:
10928774
45.
46.

Pathogenesis of gram-positive bacterial endophthalmitis.

Callegan MC, Booth MC, Jett BD, Gilmore MS.

Infect Immun. 1999 Jul;67(7):3348-56.

47.

Molecular epidemiology of Staphylococcus aureus and Enterococcus faecalis in endophthalmitis.

Booth MC, Hatter KL, Miller D, Davis J, Kowalski R, Parke DW, Chodosh J, Jett BD, Callegan MC, Penland R, Gilmore MS.

Infect Immun. 1998 Jan;66(1):356-60.

48.

Pseudomonas deficient in protease IV has significantly reduced corneal virulence.

Engel LS, Hobden JA, Moreau JM, Callegan MC, Hill JM, O'Callaghan RJ.

Invest Ophthalmol Vis Sci. 1997 Jul;38(8):1535-42.

PMID:
9224281
49.

Specific roles of alpha-toxin and beta-toxin during Staphylococcus aureus corneal infection.

O'Callaghan RJ, Callegan MC, Moreau JM, Green LC, Foster TJ, Hartford OM, Engel LS, Hill JM.

Infect Immun. 1997 May;65(5):1571-8.

50.

Staphylococcal accessory regulator (sar) in conjunction with agr contributes to Staphylococcus aureus virulence in endophthalmitis.

Booth MC, Cheung AL, Hatter KL, Jett BD, Callegan MC, Gilmore MS.

Infect Immun. 1997 Apr;65(4):1550-6.

Supplemental Content

Loading ...
Support Center